Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: April 17, 2006
Expiration Date: April 17, 2007
This activity consists of audio and visual recording of 8 live presentations.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Describe the potential role of pharmacogenomics in HIV treatment
- Design antiretroviral strategies that consider the most current data for:
- The risks of serious drug-drug interactions among antiretrovirals and with other prescription medications
- The management of long-term side effects of HIV therapies
- Initiating therapy, managing treatment failure, and the employment of strategic treatment interruptions
- The potential role of new and investigational antiretroviral drugs, including entry inhibitors
- Formulate appropriate management strategies unique to HIV hepatitis C virus coinfection
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Robert T. Schooley, MD
Course Chair
Member, Board of Directors
International AIDS Society–USA
Head, Division of Infectious Diseases
Professor of Medicine
University of California San Diego
San Diego, California
Stephen E. Follansbee, MD
Course Vice-Chair
Director
HIV Services
Kaiser Permanente Medical Center
San Francisco, California
Speakers
Constance A. Benson, MD
Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Division of Infectious Diseases
University of California San Diego
San Diego, California
Judith S. Currier, MD
Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
University of California Los Angeles (UCLA)
Co-Director
UCLA Center for Clinical AIDS Research and Education Center
Los Angeles
Eric S. Daar, MD
Professor of Medicine
David Geffen School of Medicine at University of California Los Angeles (UCLA)
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Torrance, California
David W. Haas, MD
Associate Professor of Medicine
Director of AIDS Clinical Trials Center
Vanderbilt University
Nashville, Tennessee
Daniel R. Kuritzkes, MD
Associate Professor of Medicine
Harvard Medical School
Director of AIDS Research
Brigham and Women’s Hospital
Cambridge, Massachusetts
Marion G. Peters, MD
John V. Carbone Endowed Chair
Professor of Medicine
Chief of Hepatology Research
University of California San Francisco
San Francisco, California
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Benson has served as a scientific advisor to Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Merck, and Tibotec. Her spouse or partner has served as a scientific advisor to Abbott, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Tanox, and Vertex, and has stock options for Monogram Biosciences and Vertex.
Dr Currier has received grants and research support from GlaxoSmithKline, Merck Theratechnologies, and Tibotec. She has served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. She has also received speaker honoraria from Bristol-Myers Squibb and Clinical Care Options, or fees for written enduring materials, Internet activities, and/or audio activities from Clinical Care Options, Massachusetts Medical Society–AIDS Clinical Care, R and R Healthcare, and UpToDate.
Dr Daar has received grants and research support from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Roche, and Schering. He has served as a consultant or scientific advisor to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Monogram Biosciences. He has also received honoraria from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Monogram Biosciences, and Virco.
Dr Follansbee has received grants and research support from Gilead, Pfizer, and Trimeris.
Dr Haas has received grants and research support from Bavarian Nordic, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, and Schering Plough.
Dr Kuritzkes has received grants and research support from Human Genome Sciences, Merck, Roche, and Schering-Plough. He has served as a consultant to Anormed, Avexa, Gilead, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, Panacos, Monogram Biosciences, Roche, Tibotec, and VirXys. He has also received honoraria from Gilead, Pfizer, Monogram Biosciences, and Merck.
Dr Peters has received grants and research support from Gilead and honoraria from Bristol-Myers Squibb, Indenix, Roche, and Shering. He has served as a consultant to Roche.
Dr Schooley has served as a consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Roche, Tibotec, and Vertex, and as a scientific advisor to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Roche, Tibotec, and Vertex. He has stock options for Monogram Biosciences. Dr Schooley’s spouse or partner has served as a consultant and scientific advisor to Abbott, Bristol-Myers Squibb, GlaxoSmithKline, and Merck.
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Major Grants from:
Bristol-Myers Squibb Co.
Substantial Grants from:
Abbott Laboratories
Gilead Sciences
Roche Laboratories/Trimeris
Tibotec Therapeutics
Generous Grants from:
Boehringer Ingelheim Pharmaceuticals, Inc.
GlaxoSmithKline
Additional support for this course was provided by:
Merck and Co., Inc.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
